Observational studyAmerican journal of clinical dermatology2025
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations.
Observational study in American journal of clinical dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treat-to-Target in Clinical Practice: Evaluating Real-World Achievement Rates Against Consensus Guidelines for Atopic Dermatitis.Dermatology and therapy · 2025Article
- The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe effectiveness of Janus kinase (JAK) inhibitors in treating atopic dermatitis (AD) is well established. However, little is known about whether disease control can be maintained with longer dosing intervals, especially in older patients who are at higher risk of adverse events from JAK inhibitors. The treat-to-target (T2T) consensus was established to guide systemic treatment in adults with AD, aiming to achieve disease control promptly and sustain it in the long term.
objectiveThe aim of this study was to evaluate the efficacy and safety of extended JAK inhibitor dosing intervals based on the T2T consensus in older adults.
methodsA prospective observational cohort study was conducted from July 2022 to February 2024. Fifty-eight elderly patients (aged ≥ 65 years) were included in the study and received upadacitinib with gradually longer dosing intervals. The primary outcome was the proportion of patients maintaining different treatment dosing intervals at the end of the follow-up, as well as the assessment of six scales at every visit.
resultsAmong the 58 patients (median [IQR] age, 70 [68-77] years) included in the study, 86.2% completed the 1-year follow-up. By the last visit, among those who completed the follow-up, 26.0% maintained a dosing interval of every 3 days, and 72.0% maintained a dosing interval of every 2 days. The overall incidence of adverse events (AEs) was 29.3% among all patients, with the most common AE reported being herpes virus infection (13.8%).
conclusionsThe dose reduction regimen guided by the T2T consensus was well tolerated in elderly patients with moderate-to-severe AD. Prolonging dosing intervals offers potential benefits for both patients and socioeconomic outcomes.
Indexed as
Identifiers
39939577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.